Key Highlights
- RenovaCare developed the CellMist System and SkinGun device, intended to spray a patient's own stem-cell suspension onto wounds and burns.
- The company faced a 2021 SEC enforcement action alleging an illegal promotional campaign tied to its shares, which it said it intended to contest.
- Its SEC filing record effectively stops around 2022, with a more recent item being a proposed derivative-litigation settlement disclosed via Shareholder notice.
- RCAR trades near $0.0001 with a market Capitalization of only around a hundred dollars in the last closing session.
Once promoted as a pioneer of spray-on skin-cell therapy, RenovaCare, Inc. (OTC:RCAR) has faded into the quietest corners of the market. The company's ambitious regenerative-medicine story ran headlong into regulatory scrutiny, litigation and a long stretch of silence.
Company and Latest Development
RenovaCare, incorporated in Nevada with a corporate history rooted in New York and later Arizona and New Jersey, developed cellular therapies for skin regeneration, most notably the CellMist System and the SkinGun device intended to spray a patient's own stem-cell-containing suspension onto wounds and burns.
The company's SEC filing record is extensive but effectively stops around 2022, with its most recent annual and quarterly reports on EDGAR dating to that period. A notable more recent item was a proposed derivative-litigation settlement, disclosed via a shareholder notice. Beyond that, verifiable operational news has been scarce.
What Is Driving Attention Around RCAR?
There is no single, confirmed catalyst driving RCAR today; the company has gone quiet. Much of the stock's notoriety stems from a 2021 U.S. Securities and Exchange Commission enforcement action alleging an illegal promotional campaign tied to the company's shares, which the company said at the time it intended to contest.
Combined with management changes and the 2022 termination of a research-and-development arrangement with StemCell Systems, these events help explain why the shares collapsed to sub-penny levels and why trading is now thin and sporadic rather than news-driven.
Key Numbers and Company Position
Verifiable current figures are minimal. Market-data providers show RCAR changing hands near $0.0001 with a market capitalization of only around a hundred dollars, a level that signals a near-abandoned listing rather than a Going Concern with meaningful Equity value.
Because current audited financials are not being filed, cash position, Burn Rate and liabilities cannot be independently confirmed. Investors should treat any aggregator-sourced fundamentals as unverified given the company's dormant filing status.
What Could Come Next?
For RenovaCare, the plausible paths are administrative or transactional rather than clinical. Resolution details of the derivative settlement, any resumption of SEC reporting, a change of control, or a Reverse merger that repurposes the shell would be the developments to confirm through primary filings.
There is no announced clinical trial, FDA submission or product launch on any verifiable timeline, so the SkinGun and CellMist programs cannot be assumed to be advancing.
Risks to Watch
The risks are severe. A history of SEC enforcement allegations, litigation and lapsed reporting all weigh on credibility and transparency. Sub-penny OTC status brings extreme illiquidity, wide spreads and a real risk of total loss.
Without current financials, going-concern uncertainty cannot be ruled out, and any future financing could be dilutive. The regenerative-medicine thesis remains unproven at the commercial level.
Regulatory Trouble Overwhelmed a Promising Concept
RenovaCare's journey from buzzy spray-on-skin innovator to dormant sub-penny listing is a cautionary study in how regulatory and governance problems can overwhelm a promising scientific concept. With shares near a fraction of a cent, no current SEC filings and no verifiable pipeline catalyst, RCAR is a distressed, speculative name.
Investors may want to monitor EDGAR for any renewed disclosure or corporate action, and to weigh the documented legal and liquidity risks before assigning it any forward-looking value.






Please wait processing your request...